Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Regulatory & Legal

TITLE:

NMA: EMA press release on PRAC recommendation to introduce additional restrictions on the use of Zinbryta (daclizumab) in the treatment of multiple sclerosis due to the risk of serious liver injury.

BRIEF:

NMA reports that Zinbryta should only be used in a limited group of patients under strict hepatic monitoring conditions. Currently, for the reduction of risks, physicians are advised to prescribe Zinbryta only to patients with recurrent multiple sclerosis and with inadequate response to at least two disease-modifying therapies and who can not be given other therapies of modifying evolution of the disease.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company